Biofunctionalization of cardiovascular stents to induce endothelialization: Implications for in-stent thrombosis in diabetes

Isra Marei1,2*, Blerina Ahmetaj-Shala2 and Chris R. Triggle1*

1Department of Pharmacology, Weill Cornell Medicine - Qatar, Doha, Qatar, 2National Heart and Lung Institute, Imperial College London, London, United Kingdom

Stent thrombosis remains one of the main causes that lead to vascular stent failure in patients undergoing percutaneous coronary intervention (PCI). Type 2 diabetes mellitus is accompanied by endothelial dysfunction and platelet hyperactivity and is associated with suboptimal outcomes following PCI, and an increase in the incidence of late stent thrombosis. Evidence suggests that late stent thrombosis is caused by the delayed and impaired endothelialization of the lumen of the stent. The endothelium has a key role in modulating inflammation and thrombosis and maintaining homeostasis, thus restoring a functional endothelial cell layer is an important target for the prevention of stent thrombosis. Modifications using specific molecules to induce endothelial cell adhesion, proliferation and function can improve stents endothelialization and prevent thrombosis. Blood endothelial progenitor cells (EPCs) represent a potential cell source for the in situ-endothelialization of vascular conduits and stents. We aim in this review to summarize the main biofunctionalization strategies to induce the in-situ endothelialization of coronary artery stents using circulating endothelial stem cells.

KEYWORDS
in-stent thrombosis, diabetes, cellular dysfunction, endothelialization, endothelial progenitor cells, biofunctionalization, cell capture

Introduction

Cardiovascular diseases are the most prevalent non-communicable diseases worldwide, accounting for 31% of all deaths (WHO, 2017). Coronary artery disease (CAD) is the most common type of cardiovascular disease, causing the majority of cardiovascular-related deaths worldwide (Okraienec et al., 2004). The main cause of CAD is the accumulation of fatty and fibrous materials in the wall of the coronary artery forming an atherosclerotic lesion, which eventually leads to arterial occlusion (Ross, 1993). The growing size of the formed lesion can be sufficient to block the blood flow, however most clinical complications result from thrombus formation. A thrombus...
stenosis (Kipshidze et al., 2004; Otsuka et al., 2012; Chaabane denudation and platelet activation, leading to thrombosis and causes mechanical vascular injury characterized by endothelial ischemia and infarction (Lusis, 2000).

Pathogenesis of stent thrombosis: Role of endothelial cells

Coronary stents are prosthetic cylindrical meshes inserted into the coronary artery using a catheter to relieve the narrowing of the artery and improve blood flow to the heart muscle (Meads et al., 2000). Stents provide a permanent scaffolding for the vessel wall, thus inhibiting the arterial recoil and restenosis associated with plain old balloon angioplasty (Meads et al., 2000; Garcia-Garcia et al., 2006; Seabra-Gomes, 2006). To improve the outcomes of PCI, stents have evolved in terms of design and composition, from bare metal stents (BMS), to drug eluting stents (DES) and bioreorbable vascular scaffolds (BRS). We refer the reader to these reviews on the evolution of stents types, designs and materials (O’Brien and Carroll, 2009; Borhani et al., 2018; Torii et al., 2020; Scafa Udrıște et al., 2021).

Stent thrombosis is the occlusion of a coronary artery stent by a thrombus. Standard definitions and classifications of stent thrombosis has been proposed by the Academic Research Consortium (ARC) (Garcia-Garcia et al., 2018). Stent thrombosis is classified into early, late or very late thrombosis according to the elapsed time from stent implantation, and could also be defined according to the degree of certainty as definite, probable, or silent occlusion (Garcia-Garcia et al., 2018). The reported incidence of stent thrombosis was< 1% for early stent thrombosis (D’Ascenzo et al., 2013), 0.5–1% for late stent thrombosis (D’Ascenzo et al., 2013) and 0.2–0.4% per year for very late stent thrombosis with second generation DES while 2% was reported with 1st generation DES (Biondi-Zoccai et al., 2006). Although stent thrombosis incidence remains low, it constitutes a significant public health issue due to the high number of implanted stents worldwide and the major consequences of thrombotic events (Gori et al., 2019). The mortality caused by stent thrombosis has been reported to be as high as 45% (Biondi-Zoccai et al., 2006). Additionally, stent thrombosis was shown to be accountable for 20% of all myocardial infarction cases following PCI (Gori et al., 2019). Four factors have been identified to influence stent thrombosis including the used device, implantation procedure, patient status, and type of lesion.

The pathophysiological response to stent implantation involves wound healing processes including thrombosis, inflammation, and remodeling (Chaabane et al., 2013). The stenting process leads to a partial or complete denudation of the endothelial cell layer, stretching of the artery, and mechanical vascular injury. This induces platelet activation and adhesion, and the deposition of fibrin on the site of injury. The activated platelets express adhesion molecules, such as P-selectin, which leads to the recruitment of inflammatory cells (Costa and Simon, 2005). The recruited platelets and leukocytes respond by releasing growth factors and cytokines that induce smooth muscle cell proliferation, migration, and deposition of extracellular matrix proteins in the intima of the artery, leading to in-stent restenosis (Chaabane et al., 2013).

Endothelial cells play an important role in protecting from thrombosis and inflammation and maintaining blood fluidity.
The release of vasoprotective and thromboresistant agents such as Nitric oxide (NO) and prostacyclin prevents platelet activation and thrombus formation. Von Willebrand factor secretion is also an important factor that modulates platelets adhesion and aggregation under shear conditions (van Hinsbergh, 2012). Additionally, the normal endothelium activates fibrinolysis through the secretion of tissue plasminogen activator, an important mechanism for the resolution of thrombi (Oliver James et al., 2005). Endothelial injury leads to a disturbed production of these protective molecules, and an increase in the expression of adhesion molecules leading to thrombosis, leukocyte recruitment and smooth muscle cell dysregulation (van Hinsbergh, 2012).

The vascular endothelium is also an important interface between the vascular wall and the blood components, and its absence leads to the exposure of the subendothelial elements. The direct interaction of the blood with the subendothelial elements might trigger platelet adhesion leading to thrombosis (Palmaz, 1992). Additionally, implanted stent strut or coating material may induce stent thrombosis (Palmaz, 1992; Jaffer et al., 2015; Georgiadou and Voudris, 2017). It has been determined that the degree of stent coverage with endothelial cells is “the most powerful histological predictor” of stent thrombosis (Finn et al., 2007; Georgiadou and Voudris, 2017). Additionally, the degree of neointima formation following mechanical injury was found to be correlated with the rate of re-endothelialization (Douglas et al., 2013). The delayed stent coverage with endothelial cells in addition to the constant fibrin deposition and inflammation are associated with late and very late stent thrombosis, and the risk is greatly increased in stents with more than 30% uncovered struts (Finn et al., 2007; Claessen et al., 2014).

The stent design and composition are of the main factors that influence stent endothelialization and endothelial cell recovery following PCI (Cornelissen and Vogt, 2019). The surface topography of the stent affects cell adhesion and alignment. It has been shown that a topography resulting in elongated and aligned cells could accelerate the development of a healthy endothelium layer (Claessen et al., 2014). Additionally, the non-physiological nature of the stent material could affect the migration and adhesion of endothelial cells and thus biocompatibility is a key factor in improving endothelialization (Van der Heiden et al., 2013). Endothelialization is also influenced by the thickness of the strut and was shown to be improved in stents with thinner struts (Cornelissen and Vogt, 2019). Additionally, the types of drugs and polymers used in the stent affect cell adhesion and proliferation. While the antiproliferative drugs used in DES reduce neointima formation and in-stent restenosis, they also delay the endothelialization of the stent leading to late stent thrombosis (Finn et al., 2007). The incidence of thrombosis in BMS and DES was not shown to be different, and the polymers used in BRS were shown to induce thrombosis (Buchanan et al., 2012). To reduce the occurrence of thrombotic events, dual anti-platelet therapy (aspirin and a P2Y12 inhibitor) is given to patients following PCI (Seabra-Gomes, 2006).

Stent thrombosis and diabetes

In diabetes mellitus, patients usually present with platelet dysfunction, hyperactivity or hypo-responsiveness, increasing their risk of stent thrombosis (Yuan and Xu, 2018). Additionally, the vascular endothelium is dysfunctional in response to hyperglycemia, and the proliferation and wound healing responses are impaired in this subgroup of patients (Triggle et al., 2020). Hyperglycemia results in the impairment of endothelial cells, reducing the generation of the vasodilator NO, thus favoring a vasoconstrictive state through the increase in vasoconstrictors and pro-thrombotic mediators, endothelin-1 (ET-1) and thromboxane A2 (TXA2). This imbalance disturbs the vascular tone and results in an increase in smooth muscle proliferation and migration, accompanied by an increased secretion of inflammatory cytokines and prothrombotic factors. The reduction in NO, and the increase of ET-1 and TXA2 induces platelet activation and thrombosis with the potential contribution of an elevated generation of prostacyclin that activates TXA2 receptors (Beckman et al., 2002; Seabra-Gomes, 2006; Vanhoutte and Tang, 2008). These conditions promote thrombus formation (Figure 1A). The incidence of stent thrombosis in patients with diabetes was found to be double that for patients without diabetes (Wiviott et al., 2008). Additionally, insulin was found to play a major role in influencing thrombosis. The chronic activation of endothelial cells by insulin might affect the production of vasoprotective and antithrombotic factors, activating a prothrombotic and proinflammatory status (Wu and Thiagarajan, 1996; Angiolillo et al., 2005). The prothrombotic status in these patients decreases their response to anti-platelet agents. The dysfunctional platelets in patients with diabetes are less sensitive to aspirin increasing their risk of ischemic events (Gum et al., 2003; Watala et al., 2004; Angiolillo et al., 2005). There is also evidence of the negative effect of the common anti-diabetes drug, metformin, on endothelial proliferation on stents releasing mTOR inhibitors, as was shown in vitro and in rabbit model (Habib et al., 2013a; Habib et al., 2013b). In terms of the time of occurrence, a meta-analysis of stent thrombosis in patients with and without diabetes have shown that both subgroups had a similar rate of early stent thrombosis following PCI with DES, however, diabetes was associated with an increase in the incidence of late stent thrombosis (Yuan and Xu, 2018).

Given the important role of the endothelium in the protection from thrombosis, re-endothelialization is a key therapeutic target to improve the outcomes of stent implantation in patients with diabetes, and to maintain an antithrombotic and anti-inflammatory status at the site of implantation (Douglas et al.,
2013). The gradual endothelialization of stents protects from the thrombotic events, however, this process is slow in BMS, and the drugs used in DES inhibit endothelial cell proliferation and complete coverage. Thus, there is a need for a modulation in the composition of the stents to induce rapid endothelial cell adhesion and proliferation and full stent coverage soon after implantation.

Stent biofunctionalization to induce endothelialization with circulating endothelial progenitor cells

Endothelialization of stents happens through two main mechanisms: (I) the proliferation and migration of the...
resident cells at the site of injury, and (II) the homing and adhesion of circulating endothelial progenitor cells (EPCs) (Ong et al., 2005) (Figure 1B). Mature endothelial cells have a low proliferation and replication capacity, thus their participation in the endothelialization process is slow and limited. It is hypothesized that EPCs play a major role in the endothelialization process. EPCs are progenitors that circulate in the blood and have the ability to differentiate to mature endothelial cells and to participate in angiogenesis and neovascularization processes (Medina et al., 2017). Since their discovery by Asahara et al. (1997) in 1997, many attempts have been made to isolate EPCs using varying methods, which resulted in the identification of multiple cell populations that have been categorized under the EPC terminology (Medina et al., 2017). The main identified subpopulations are early EPCs (expressing CD31, CD45 and CD14, and lack expression of CD133) and late EPCs (expressing CD34, CD31 and CD133 and lack expression of the hematopoietic markers CD45, CD14, and CD115) (Tura et al., 2013; O’Neill TJ;Wamhoff et al., 2005; Zentilin et al., 2006). The late EPCs have been recently recognized to be the “true EPCs” due to their ability to differentiate into a stable mature endothelial phenotype, and to participate directly in the neovascularization process by incorporating into the vasculature (Yoder et al., 2007; Medina et al., 2010a; Keighron et al., 2018). A recent study used single-cell RNA-sequencing analysis (scRNA-seq) to identify specific markers in late EPCs, and found that this subpopulation expressed high levels of bone morphogenetic protein 2 and 4 (BMP 2 and 4) and ephrin B2 (EFNB2) when compared to other types of endothelial cells (Abdelgawad et al., 2021). BMP 2 and 4 were also found to be selectively expressed by late, but not, early EPCs, and to regulate EPC commitment and angiogenic potential (Smadja et al., 2008). Late EPCs and HUVECs share high expression of neuropilin 1 (NRP1) and Vascular endothelial growth factor (VEGF-C) (Abdelgawad et al., 2021), both important factors for the differentiation of endothelial precursors (Cimato et al., 2009; Zhang et al., 2019; Abdelgawad et al., 2021). This expression pattern could be used for the identification and differentiation between subpopulations of EPCs. We refer the reader to these reviews on the detailed differences between these subtypes and their therapeutic potential in many settings including diabetes (Medina et al., 2010b; Yoder, 2012; Pelliccia et al., 2022a; Triggle et al., 2022a).

Biofunctionalization of blood contacting implants and stents using attracting molecules (such as antibodies, proteins, glycosaminoglycan (GAGs), peptides and aptamers) have been proposed to induce endothelialization (Figure 1C). Other delivery approaches have been investigated such as nanoparticles and magnetic molecules. These modifications provide mimicry factors that aim to induce cell capture, adhesion, and proliferation of endothelial progenitors and/or influence their mobilization, taking advantage of their ability to migrate to the site of injury during vascular repair processes. Table 1 summarized some of the recent studies investigating the use of these factors to induce stent endothelialization. We also refer the reader to a comprehensive review on the chemistry aspect of biofunctionalization to incorporate these molecules into the surfaces of medical devices (Spicer et al., 2018).

To this date, the main clinically applied biofunctionalization strategy to induce EPCs capture and stent endothelization is the use of monoclonal antibodies against CD34, represented by the Genous™ EPC capture stent and the COMBO bio-engineered stent (OrbusNeich, Florida, United States) (Klomp et al., 2009; Tomasevic et al., 2019) (Table 1). CD34 biofunctionalized stents showed a great promise in early in vivo models, as they resulted in the rapid endothelialization of stents in a murine model (Kutryk and Kuliszewski, 2003). Also, early ex-vivo and clinical studies showed the rapid endothelialization of BMS (Larsen et al., 2012) and DES (Granada et al., 2010; Nakazawa et al., 2010), and for that it was hypothesized that these stents will protect from stent thrombosis. Despite their initial promise, recent clinical studies comparing the performance of the Genous™ EPC capture stent with DES didn’t show superior results in terms of their protection from lumen loss and restenosis. Studies including the TRIAS-HR (71), HEALING and HEALING II (Duckers et al., 2007) showed that the Genous stent was associated with a trend towards increase in target vessel failure. In light of these findings, it was thought that combining the CD34 capture antibody with an anti-proliferative drug will improve these outcomes, thus the novel COMBO bio-engineered stent was developed.

The COMBO bio-engineered stent (OrbusNeich, Florida, United States), is a new generation DES which contains a sirolimus-releasing resorbable polymer matrix to reduce restenosis, in addition to the CD34 coating to induce endothelialization. Although comparative clinical trials have shown that COMBO stents were non-inferior to other DESs including TaxusLiberte™ (REMEDEE randomized study) (Haude et al., 2013), and Xience™ (HARMONEE randomized study) (Saito et al., 2018), the COMBO stents were associated with a trend towards increase in the rates of target vessel failure at 12 months (Saito et al., 2018; Jakobsen et al., 2021). Additionally, a recent systematic review including a total of 3961 patients and comparing the COMBO EPC-capturing DES against standard DES from 4 randomized controlled trials, showed no difference in 1-year cardiac death when compared to standard DESs. However, COMBO stent was associated with higher rates of target lesion revascularization and target vessel failure (Pelliccia et al., 2022b). Thus the benefit of these stents in inducing rapid endothelialization should be weighed against the possible risk of induced hyperplastic reactions and their consequences (Pelliccia et al., 2022b).

The use of CD34 antibody to capture EPCs has also been proposed for other medical devices, vascular grafts and tissue engineering scaffolds. Nevertheless, because CD34 is not specific
| Stent type | Material | Bioactive molecule | Biofunctionalization strategy | Outcomes | References |
|------------|----------|-------------------|-----------------------------|----------|------------|
| Clinical studies | Genous™ EPC capture stent (OrbusNeich, Florida, United States), stainless steel 316L | Marine monoclonal Anti-human CD144 antibody | Grafting coupled poly-xantherin intermediate matrix coating, immobilized with anti-human CD144 antibodies. | - Anti CD41 coated stents resulted in rapid endothelialization of stents in rabbit model (Kaneyk and Kikutake, 2003). - Clinical studies: TRAIA-IR (Klopp et al., 2011), HEALING (Aoki et al., 2005) and HEALING II (Hiroyuki et al., 2007) showed that the Genous stent was associated with a trend towards increase in target vessel failure. HEALING IR showed that although stents induced EPC recruitment, combining stent therapy with Genous stent didn‘t reduced in-stent restenosis. | (Kaneyk and Kikutake, 2003; Klopp et al., 2011; Hiroyuki Eric et al., 2007; Klopp et al., 2011; Aoki et al., 2005) |
| COMBO bio-engineered stent (OrbusNeich, Florida, United States), stainless steel 316L | Sirolimus and marine monoclonal Anti-human CD144 antibody | Sirolimus-releasing resorbable polymer matrix (Synthefy™, methacrylic-based multi-block copolymer composed of lactide-glycolide-carboxylic acid) combined with anti CD144 antibodies. | - COMBO stents were non inferior to TaxusLibertos™ (REMEDIE randomized study) (Haushe et al., 2013), and HARMONY randomized study (Saito et al., 2018) - Associated with a trend towards increase in the rate of target vessel failure at 12 months (Saito et al., 2018; Jakobsen et al., 2021). - No difference in 1-year cardiac death when compared to standard DESs. Showed higher rate of target lesion revascularisation and target vessel failure | (Haushe et al., 2013; Saito et al., 2018; Jakobsen et al., 2021; Falko et al., 2022) |
| Cobra PzF stent (Cobra, Florida, United States), Cobalt chromium (CoCr) | Fluorinated Polyene-T (PzF) polymer | Coated with a thin nano-layer of fluorinated Polyene-F (PzF) polymer, and a layer of poly (bis fluoroethoxy]phosphazene). | - PzF previously showed reduced intimal hyperplasia, anti-thrombotic, and anti-inflammatory properties (Koppara et al., 2016) and had superior healing when compared to bioabsorbable polymer DES in porcine and rabbit models (Hayashi et al., 2019). - Clinical studies: 1-year follow up showed that the stent performance is satisfactory and confirmed clinical efficacy and safety (Malladi et al., 2021) - 5 years follow up showed low incidence of major adverse clinical events, with no reported stent thrombosis throughout the 5 years. Target vessel failure increased from 11.5% at 5 months to 17.6% at 5 years (Falko et al., 2022) | (Koppara et al., 2016; Hayashi et al., 2019; Malladi et al., 2021; Ciftp et al., 2022; Cornelliski et al., 2022) |
| In vivo studies | CoCr | A leucine peptide for endothelial colony forming cell (WKYMVm) | Stents were coated with dopamine, and the peptide was conjugated to dopamine using 2imidazolinesuccinimide (NIS) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) to activate the carboxyl group of the peptide. | - In vitro: The modified stent improved the proliferation of HUVECs at day 7 of culture in comparison to BMS. - In vivo: peptide delivery to vessels was studied in rabbit iliac arteries, and peptide coating was observed up to 7 days, and diminished gradually. | (Bae et al., 2020) |
| Stainless Steel | Marine monoclonal antithrombin endoglin antibody | Commercially available stents: marine monoclonal antithrombin endoglin antibody (ENDs) (Beijing Lepu Medical Technology limited corporation, China), in comparison to sirolimus eluting stents (SESs) (Johnson & Johnson, United States), and BMS (Abbott, United States). | - Animal model: juvenile pigs. Findings: Mean neointima area and percent area stenosis were lower in ENDs and SESs compared to BMS at 14 days of implantation. Endothelial coverage of SESs was significantly higher than that of SESs and BMSs at days 7 and 14, indicating reduced endothelialization. | (Cai et al., 2014) |
| CoCr | Anti CD144 antibody and silicone (si) nanofilaments | Polished surfaces were coated with si nanofilaments Surface were treated with Ti2 plasma, followed by immersion in toluene dissolved in 3-aminopropyltriethoxysilane (APTES) to introduce amine groups. Antibodies were immobilized in the presence EDC and NHS. | - In vitro both si nanofilaments and CD144 induced EPCs and MSCs capture under dynamic conditions (15 dyn/cm²) in a perfusion pump system. Cell adhesion and spreading was improved on modified surfaces. - In vivo: stents were implanted into porcine coronary arteries for 1 week, and showed enhanced endothelial coverage in stents coated with both si nanofilaments and CD144 antibody. The modified stents reduced restenosis when compared to BMS. | (Park et al., 2020) |
| Stainless steel 316L | Recombinant antibody fragments (scFv) specific for vasculat endothelial growth factor receptor-2 (VEGFR2) | Surfaces were coated with titanium precursor followed by functionalization with amino groups and immobilization of endoxilglycolic acid covalently bonded to scFv molecules. | - In vitro: The modification didn‘t affect the metabolic activity or induce cytotoxicity of HUVECs. Adhesion of HUVECs was increased on VEGFR2 coated surfaces. - In vitro: stents were implanted into porcine arteries for 5 and 30 days. There was no evidence of neointima, thrombus, or myocardial infarction at both time points. Stent coverage was significantly higher in modified stents when compared to BMS at 5 days. No significant difference was detected at 30 days. Histological sections showed coverage with a cell layer (80 μm) by day 30. | (Wang et al., 2020) |
| Nitinol | RGD peptide and CXCL1 | Stents were coated with star-shaped polyethylene glycol (PEG), followed by immobilization of RGD alone or RGD/CXCL1 | - In vitro: increased adhesion of EOC and HUVEC to RGD and RGD/CXCL1 surfaces compared to BMS and star PEG modified surfaces. Smooth muscle cells (SMC) proliferation was not affected on RGD/CXCL1 and was reduced in star PEG surfaces. - In vivo: stents were implanted in apes at 6-11 mice for one week, and showed reduced stenosis and thrombosis in | (Simuokiatma et al., 2016) |

(Continued on following page)
| Stent type/Material | Bioactive molecule | Biofunctionalization strategy | Outcomes | References |
|---------------------|-------------------|-----------------------------|----------|------------|
| Stainless Steel     | Vasculaire endothelial calcium (VE-Cal) antibody | VE-Cal antibodies were immobilized on stainless steel stents grafted with sulfonamide zwitterionic and acrylic acid. | RGD and RGD/CXCL1 stents. Fast-PGF stents resulted in induced thrombosis. Endothelialization was increased in RGD/CXCL1 stents. | (Chan et al., 2017) |
| Titanium (Ti)       | heparin-poly-L-lysine nanoparticles | The nanoparticles were immobilized into dopamine-coated Ti surfaces. Ti disks were coated with dopamine (2 mg/ml in Tris buffer, pH 8.5) for 12 h, followed by sonication in water. The process was repeated three times to coat with three layers, followed by incubation with nanoparticle suspension at 37°C for 24 h. | - In vitro: The modified stent with the co-polymer didn’t cause blood cell or platelet adhesion or activation. Stents containing VE-Cal antibody resulted in induced EPCs adhesion and coverage, while small numbers were adhered to BMS and stents with the co-polymer alone. - In vitro: Stents were implanted into rabbit carotid artery, and showed no signs of thrombosis or restenosis following 1 month of implantation. Modified stents were completely covered with endothelial cells. Ti-modified samples were implanted into dog femoral arteries for 4 weeks. Ti surfaces showed severe thrombosis formation and thick neo-intimal formation, whereas Ti modified surfaces showed no thrombosis or neointimal thickening. The Ti modified surfaces were also covered with a confluent layer of endothelial cells. | (Liu et al., 2019) |

| As in vitro studies | CoCr | Elastin-like recombinamers (ELR) genetically modified with an REDV sequence | Plasma activation and etching using sodium hydroxide (NaOH) followed by silanization with 3-chloropropyltriethoxysilane and functionalized with the ELR. | HUVEC cell adhesion response time was directly correlated to the amount of immobilized ELR on the surface. Surfaces activated with NaOH showed better adhesion and spreading of HUVECs. | (Castellanos et al., 2015) |
| Stainless Steel 316L | Phage-identified SUS316L-binding peptide (SRF-A, VQHTKTSYTVLR), followed by anti ICAM-1 antibody modification | The SRF-A peptide was used as a linker to immobilize ICAM-1 antibody. N-terminal streptavidin-modified anti-ICAM antibody was adsorbed to SRF-A modified SUS316L disks. | The identified peptide (SRF-A) was not toxic to HUVECs. The described modification with SRF-A and anti ICAM-1 antibody enhanced HUVECs adhesion and showed higher selectivity to HUVECs over SMCs. | (Nakagaki-Mikami et al., 2020) |
| CoCr | Endothelial-specific oligomeric peptide 3 (E-SOP3) 5'-GGG AGG TGC AAG TAA ACG CTC AAC AAC GGG CCG GGT TAC ACA 7GA GGG CGG GAT C'F | Aminosilaneization using 3-(Aminopropyl) methoxysilane (APTES), followed by immobilization of 5'-fluorinated oligomeric peptide. | Porcine EPGs showed enhanced adhesion to modified surfaces, and promoted the proliferation of vascular smooth muscle cells and showed improved engraftment in 4 days of culture. | (Bonnici et al., 2017) |
| Ti | Ti oxide (TiO2) nanotubes and fibrinogen | TiO2 surfaces were anodized to create TiO2 nanotubes. Fibrinogen was immobilized on TiO2 nanotubes using polyelectrolyte multilayer coating. | The nanostructured TiO2 nanotubes enhanced the adhesion, spreading, proliferation and secretion of nitric oxide and prostacyclin in HUVECs. The nanotube tips had an inverse relationship with cytocompatibility. | (Jin et al., 2009) |
| Ti | Ti nanotubes | Anodic oxidation | Ti nanotubes induced VEGF production by macrophages. Also, they inhibited glycolysis of macrophages by activating AMPK signaling leading to reduced macrophage release of inflammatory factors and induced polarization, accelerating endothelialization. | (Yu et al., 2021) |
| Nitinol | Semi-interpenetrating network (IPN) hydrogel consisting of Polyacrylamide (PAA), polyethylene glycol (PEG), polyethylene and polyelectrolyte | Cast molding of stents in semi IPN hydrogel through free radical polymerization | Induced adhesion, proliferation, and migration of HUVECs. Reduced adhesion and proliferation of SMCs. | (Chen et al., 2019) |
| Stainless steel 316L | Recombinant antibody fragments (scFv) | Incorporating hydrogel trough-coating with titania, followed by sonication using APTES, and immobilization of glycogenated scFv. | The modification was nontoxic to the EPC line 35.1 (HsECF15.1) and maintained their viability on modified surface. | (Forstner et al., 2016) |
| bioabsorbable magnesium alloy MgZn20Nd | Amino-locine-based poly (ether amine) urethane (Arg-Lys-PEGUA) in comparison to poly glycolide-co-lactide (PGLA) coating | Spinning coating of disks with the polymers (Arg-Leu-PEGUA in N,N-Dimethylformamide (DMF) or PGLA in Dichloromethane CH2Cl2) followed by solvent evaporation and heating. | Enhanced HUVEC viability, which was proportionally related to arg ratio. HUVEC increased NO production. Viability of SMCs was not affected by the peptide. | (Liu et al., 2017; Liu et al., 2017) |
| Ti | Heparin-VEGF-Biosensor | Layer-by-layer coating | The modification resulted in reduced platelet adhesion and aggregation and prolonged partial thromboplastin and prothrombin time, compared to unmodified Ti. HUVEC adhesion and proliferation were induced on modified surfaces. | (Wang et al., 2012) |
| PEG-diucrylate (PEGDA) hydrogel | REDV-containing peptides | Peptides that target αIIb and αIIa were coupled to PEGDA hydrogel using these combinations RGD+ REDV, CRRETAVGCY(cyclic)+REDV, P_BGDG+KSP_REDV, P_BGDG+P_REDV, P_BGDG+P_REDV | Reduced bio EPGs capture under dynamic conditions in a parallel plate flow chamber system at 28 °C, and resulted in higher in vitro performances and velocity fluctuations. | (Tian et al., 2022) |
to EPCs, it has been suggested that other CD34 positive cells in the blood will compete with EPCs to adhere to the immobilized antibody (Sidney et al., 2014). This could be a contributing factor to the hyperplasia observed in the CD34 biofunctionalized stents. The use of other antibodies against CD133, and VE-Cadherin, amongst other antigens, have been reported to influence EPCs capture, however these stents have met mixed success in vivo (Sedaghat et al., 2013; Van der Heiden et al., 2013). Therefore, there is a need to incorporate other specific bioactive moieties to induce the specific recruitment of EPCs without inducing hyperplasia and restenosis.

Other EPC capturing strategies have been investigated in vitro and in vivo, however these approaches are yet to be validated and translated to clinical use (Table 1 respectively). Growth factors such as vascular endothelial growth factor (VEGF) have been used to induce EPCs adhesion and growth (Van der Heiden et al., 2013). Mobilization of stem cells using chemokines such as stromal cell derived factor 1a (SDF-1a) have also been investigated (Zhang et al., 2011). However, these factors are not specific to EPCs and might result in similar outcomes to what has been observed in CD34 coated stents.

A more specific approach to capture EPCs is the use of specific short peptide ligands and aptamers. These ligands provide an advantage over large biomolecules, because controlling the configuration and folding of large biomolecules is challenging during the biofunctionalization process. The literature describes the use of peptides with different specificities: (i) metal-binding peptides, (ii) non-specific cell adhesion peptides, (iii) endothelial cell-specific peptides and (iv) EPC-specific peptides. Metal-binding peptides are used as linkers to allow further modifications of the stent surface. Examples include the stainless-steel specific peptide SBP-A (Sakaguchi-Mikami et al., 2020).

One of the commonly used peptides that has shown enhanced cell biocompatibility is RGD (Arginyl-glycyl-aspartic acid) peptide, which is the principle ligand responsible for cell binding to the ECM (Bellis, 2011). Other peptides have been investigated such as the laminin derived sequences IKVAV (isoleucine-lysine-valine-alanine-valine) and YIGSR (Tyrosine-Isoleucine-Glycine-Serine-Arginine) (Massia and Hubbell, 1991; Grant et al., 1992). These peptides enhance the non-specific adhesion of cells to biofunctionalized surfaces. Peptides targeting endothelial cells have also been investigated, including REDV (Arginine-Glutamate-Aspartate-Valine) (Hubbell et al., 1991). Specific peptides to EPCs have been identified such as the disulfide cyclic octa-peptide (cGRGDcvc, also known as LXW7) (Hao et al., 2017), TPS (Threonine-Proline-Serine-Leucine-Glutamate-Glutamine-Arginine-Threonine-Valine-Tyrosine-Alanine-Lysine) (Veleva et al., 2007), and WKYMVm (Trp-Lys-Tyr-Met-Val-D-Met) (Bae et al., 2020a). These peptides interact with the integrins -which are adhesion receptors on the cells - and activate them, resulting in enhanced cell adhesion and binding. EPCs specific aptamers or oligonucleotides have been also tested (Barsotti et al., 2015). These bioactive molecules hold a great promise for the biofunctionalization of stents due to their specificity and ease of incorporation.

Challenges facing stent endothelialization with EPCs

One of the main challenges facing the in situ endothelialization with circulating EPCs is their low numbers in the blood (Yoder, 2012). These numbers were also shown to be reduced in disease states such as diabetes. Thus, strategies to boost the numbers of EPCs might be required. One example is the use of pharmacological induction using agents with known effects on EPCs such as statins. It was observed during the HEALING IIB study that statin therapy has increased the numbers of EPCs by 5.6-fold, and that the combination of statin therapy with EPC capturing stents resulted in optimal coverage of the stents (den Dekker et al., 2011). EPCs numbers could be boosted by other strategies such as combining more than one capturing molecule or incorporating chemokine or growth-factor-releasing nanoparticles within the coating of the stent. Additionally, local or systematic injection of autologous EPCs could help to boost the endothelialization of the stent.

Another limitation of stent endothelialization with EPCs is the variability in the intrinsic regenerative potential between patients, which might be affected by diabetes, cardiovascular diseases or other comorbidities (Emmert and Hoerstrup, 2016). This is important to consider particularly because the whole concept of in situ endothelialization depends on the intrinsic regenerative potential, and any impairment of this potential will affect the rate of endothelialization (Stassen et al., 2017). It was shown that EPCs function and regenerative ability is impaired in diabetes (Triggle et al., 2022b). This, in addition to vascular endothelial dysfunction, reduces the potential of stent coverage. Thus, enhancing endothelial and EPC function in these patients should be a target to improve endothelialization, in combination with stent biofunctionalization. Antidiabetic drugs with endothelial and cardioprotective effects (such as vildagliptin) (Lee et al., 2019) could be investigated in combination with the biofunctionalized stents.

In conclusion, stent endothelialization represents a potential target to reduce in-stent thrombosis following PCI. Specific biofunctionalization of stents is required to induce endothelialization without evoking restenosis. Targeting EPC and endothelial dysfunction in diabetes are key strategies to aid in the endothelialization process.

Author contributions

IM and CT developed the theoretical framework of the manuscript. IM wrote the manuscript. IM, CT, and BA-S reviewed and edited the manuscript.
Funding
This work was made possible by an Early Career Researcher Award ECRA02-007-3-006 from the Qatar National Research Fund (a member of The Qatar Foundation). IM is supported by the L’Oréal-UNESCO For Women in Science Young Talents Program/Middle East, 2020. The statements made herein are solely the responsibility of the authors. BA-S is funded by the British Heart Foundation Imperial Centre of Research Excellence Award—RE/18/4/34215.

Acknowledgments

Figure 1 was created using BioRender.com.

References

Abdelgawad, M. E., Desterke, C., Uzan, G., and Naserian, S. (2021). Single-cell transcriptomic profiling and characterization of endothelial progenitor cells: new approach for finding novel markers. Stem Cell Res. Ther. 12 (1), 145. doi:10.1086/s13287-021-02185-0

Angiolillo, D. J., Fernandez-Ortiz, A., Bernardi, E., Ramirez, C., Sabate, M., Jimenez-Quevedo, P., et al. (2005). Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54 (8), 2430–2435. doi:10.2337/diabetes.54.8.2430

Aoki, J., Serruys, P. W., van Beusekom, H., Ong, A. T., McFadden, E. P., Sianos, G., et al. (2005). Endothelial progenitor cell capture by stents coated with antibody against CD34: The HEALING-FIM (healthy endothelial accelerated lining inhibits growth and neointimal growth) registry. J. Am. Coll. Cardiol. 45 (10), 1574–1579. doi:10.1016/j.jacc.2005.01.048

Ashaara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., et al. (1997). Isolation of putative progenitor endothelial cells for angiogenesis. Sci. (New York, NY) 275 (5302), 964–967. doi:10.1126/science.275.5302.964

Bae, I.-H., Jeong, M. H., Park, D. S., Lim, K. S., Shim, J. W., Kim, M. K., et al. (2020). Mechanical and physio-biological properties of peptide-coated stent for re-endothelialization. Biomater. Res. 24, 4. doi:10.1002/jbm.a.35461

Bae, I.-H., Jeong, M. H., Park, D. S., Lim, K. S., Shim, J. W., Kim, M. K., et al. (2020). Mechanical and physio-biological properties of peptide-coated stent for re-endothelialization. Biomater. Res. 24 (1), 4–9. doi:10.1002/jbm.a.35461

Barsotti, M. C., AlKayal, T., Tedeschi, L., Dinucci, D., Losi, P., Sbrana, S., et al. (2015). Oligonucleotide biofunctionalization enhances endothelial progenitor cell adhesion on cobalt/chromium stents. J. Biomed. Mat. Res. A 103 (10), 3284–3292. doi:10.1002/jbm.a.35461

Beckman, J. A., Creager, M. A., and Libby, P. (2002). Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 289 (19), 2570–2581. doi:10.1001/jama.289.19.2570

Bellis, S. L. (2011). Advantages of RGD peptides for directing cell association with biomaterials. Biomaterials 32 (18), 4205–4210. doi:10.1016/j.biomaterials.2011.02.029

Biondi-Zoccai, G. G., Agostoni, P., Sangiorgi, G. M., Airoldi, F., Cosgrave, J., Cheffo, A., et al. (2006). Incidence, predictors, and outcomes of coronary dissections left untreated after drug-eluting stent implantation. Eur. Heart J. 27 (5), 540–546. doi:10.1093/eurheartj/ehh181

Bitt, J. A. (2015). Percutaneous coronary interventions in the diabetic patient: Where do we stand? Circ. Cardiovasc. Interv. 8 (4), e00944. doi:10.1161/CIRCINTERVENTIONS.114.001944

Borhani, S., Hassanajili, S., Ahmadi Tafsi, S. H., and Rabban, S. (2018). Cardiovascular stents: overview, evolution, and next generation. Prog. Biomater. 7 (3), 175–205. doi:10.1007/s40204-018-0097-y

Buchanan, G. L., Basavarajiah, S., and Cheffo, A. (2012). Stent thrombosis: Incidence, predictors and new technologies. Thrombosis 2012, 956062. doi:10.1155/2012/956062

Castellanos, M. I., Zenses, A-S., Grau, A., Rodriguez-Cabello, J. C., Gil, F. J., Manero, A., J., et al. (2015). Biofunctionalization of REDV elastin-like recombinamers improves endothelialization on CoCr alloy surfaces for cardiovascular applications. Colloids Surf. B Biointerfaces 127, 22–32. doi:10.1016/j.colsurfb.2014.12.056

Chaahane, C., Onuka, F., Virmani, R., and Bochaton-Piallat, M. L. (2013). Biological responses in stented arteries. Cardiovasc. Res. 99 (2), 353–363. doi:10.1093/cvr/cvt115

Chen, H., Wang, X., Zhou, Q., Xu, P., Liu, Y., Wan, M., et al. (2017). Preparation of vascular endothelial cadherin loaded-amphiphilic copolymer decorated coronary stents for Anticoagulation and endothelialization. Langmuir 33 (40), 13450–13457. doi:10.1021/acs.langmuir.7b03064

Cimato, T., Beers, J., Ding, S., Ma, M., McCoy, J. P., Boehm, M., et al. (2009). Neuripin-1 Identifies endothelial precursors in human and murine embryonic stem cells before CD34 expression. Circulation 119 (16), 2170–2178. doi:10.1161/CIRCULATIONAHA.109.849596

Claessen, B. E., Henriques, J. P., Jaffer, F. A., Mehran, R., Piek, J. J., and Dangas, G. D. (2014). Stent thrombosis: A clinical perspective. JACC Cardiovasc. Interv. 7 (10), 1081–1092. doi:10.1016/j.jcin.2014.05.016

Cornellissen, A., Sakamoto, A., Sato, Y., Kawakami, R., Mori, M., Kawai, K., et al. (2022). COBRA PzF™ coronary stent in clinical and preclinical studies: setting the stage for new antithrombotic strategies? Future Cardio. 18 (3), 207–217. doi:10.21277/fca-2021-0057

Cornellissen, A., and Vogt, F. J. (2019). The effects of stenting on coronary endothelium from a molecular biological view: time for improvement? J. Cell. Mol. Med. 23 (1), 39–46. doi:10.1111/jcmm.13936

Costa, M. A., and Simon, D. I. (2005). Molecular basis of restenosis and drug-eluting stents. Circulation 111 (17), 2257–2273. doi:10.1161/CIRCULATIONAHA.104.53645.77

Cui, S., Liu, J.-H., Song, X.-T., Ma, G.-L., Du, B.-J., Lv, S.-Z., et al. (2014). A novel stent coated with antibodies to endoglin inhibits neointimal formation of porcine coronary arteries. Biomed. Res. Int. 2014, 428619. doi:10.1155/2014/428619

Cui, S., Song, X.-T., Ding, C., Meng, I.-J., Lv, S.-Z., and Li, K. (2015). Comparison of reendothelialization and neointimal formation with stents coated with antibodies against endoglin and CD34 in a porcine model. Drug Des. Devel. Ther. 9, 2249–2256. doi:10.2147/DDDT.S81257

Cutlip, D. E., Jauhar, R., Meraj, P., Garratt, K. N., Novack, V., Novack, L., et al. (2002). Five-year clinical outcomes of the cobra polyzene f nanocoated coronary stent system. Cardiovasc. Revasc. Med. 41, 76–88. doi:10.1016/j.carrev.2002.12.030

D’Ascanzo, F., Bollati, M., Clementi, F., Castagnoli, D., Lagerqvist, B., de la Torre Hernandez, J. M., et al. (2013). Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221, 066 patients, and 4276 thromboses. Int. J. Cardio. 167 (2), 575–584. doi:10.1016/j.ijcard.2012.01.080

den Dekker, W. K., Houtgraaf, J. H., Onuma, Y., Benit, E., de Winter, R. J., Wijns, W., et al. (2011). Final results of the HEALING IIb trial to evaluate a bio-engineered

Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
et al. (1992). Interaction of endothelial cells with a laminin A chain peptide.

Arch. Cardiol. Mex. 137 (24), 2635.

Hell. J. Cardiol. 2011 (4), 419–421. doi: 10.4244/EIJ-D-16-00354

Keighron, C., Lyons, C. J., Creane, M., O’Brien, T., and Liew, A. (2014). Recent advances in endothelial progenitor cells toward their use in clinical translation. Front. Med. 5, 354. doi: 10.3389/fmed.2018.00354

Kipshidze, N., Dangas, G., Taşpenko, M., Moses, J., Leon, M. B., Kutyrk, M., et al. (2004). Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J. Am. Coll. Cardiol. 44 (4), 733–739. doi: 10.1016/j.jacc.2004.04.048

Klop, M., Meij, A. M., Varma, C., Koolen, J. J., Teiger, E., Richardson, G., et al. (2011). 1-year outcome of TRIASS HR (TRI-stent adjudication study-high risk of restenosis) a multicenter, randomized trial comparing genous endothelial progenitor cell capturing stents with drug-eluting stents. JACC. Cardiovasc. Int. 4 (8), 896–904. doi: 10.1016/j.jcin.2011.05.011

Klop, M., Meij, A. M. V., Varma, C., Koolen, J. J., Teiger, E., Richardson, G., et al. (2011). 1-year outcome of TRAAS HR (TRI-stent adjudication study-high risk of restenosis) a multicenter, randomized trial comparing genous endothelial progenitor cell capturing stents with drug-eluting stents. JACC. Cardiovasc. Int. 4 (8), 896–904. doi: 10.1016/j.jcin.2011.05.011

Kong, D., Melo, L. G., Manga, A. A., Zhang, L., Lopez-Illasaca, M., Perrella, M. A., et al. (2004). Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation 109 (14), 1768–1775. doi: 10.1161/01.CIR.0000121732.85752.6F

Koppura, T., Sakakura, K., Pacheco, E., Cheng, Q., Zhao, X., Acampado, E., et al. (2016). Preclinical evaluation of a novel polyphosphazene surface modified stent. Int. J. Cardiovasc. Interv. 22, 217–225. doi: 10.1055/s-0036-1587872.181

Koskinas, K. C., Siontis, G. C., Piccolo, R., Franzone, A., Haynes, A., Rat-Würtzler, E., et al. (2016). Impact of diabetic status on outcomes after revascularization with drug-eluting stents in relation to coronary artery disease complexity: patient-level pooled analysis of 6081 patients. Circ. Cardiovasc. Int. 9 (2), e003255. doi: 10.1161/CIRCINTERVENTIONS.115.003255

Kutyrk, M. J., and Kuluzewski, M. (2003). In vivo endothelial progenitor cell seeding for the accelerated endothelialization of endovascular devices. NEW YORK, NY 10011 USA: American Journal of Cardiology: 2003 EXCERPTA MEDICA INC. 650 AVENUE OF THE AMERICANS

Larsen, K., Cheng, C., Tempel, D., Parker, S., Yazdani, S., den Dekker, W. K., et al. (2012). Capture of circulary endothelial progenitor cells and accelerated re-endothelialization of a bio-engineered stent in human ex vivo shunt and rabbit denudation model. Eur. Heart J. 33 (1), 120–128. doi: 10.1093/eurheartj/ehr196

Lee, C. H., Hsing, M. J., Chang, S. H., Hung, K. C., Wang, C. J., Hsu, M. Y., et al. (2019). Nanotubular vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: In vitro and in vivo. Int. J. Nanomedicine 14, 7503–7513. doi: 10.2147/IJN.S214189

Liu, J., Wang, P., Chu, C.-C., and Xi, T. (2017). A novel biodegradable and biologically functional arginine-based poly (ester urethane) coating for Mg-Zn-Nd alloy: enhancement in corrosion resistance and biocompatibility. J. Mat. Chem. B 5 (9), 1787–1802. doi: 10.1039/c6tb03147a

Liu, J., Wang, P., Chu, C.-C., and Xi, T. (2017). Arginine-based polyurethane coating for Mg-Zn-Nd alloy: enhancement in corrosion resistance and biocompatibility. Colloids Surf. B Biointerfaces 159, 78–88. doi: 10.1016/j.colsurfb.2017.07.031

Liu, T., Zeng, Z., Liu, Y., Wang, J., Maitz, M. F., Wang, Y., et al. (2014). Surface modification with dopamine and heparin/poly-L-lysine nanoparticles provides a favorable release behavior in cardiovascular lesion. ACS Appl. Mater. Interfaces 6 (11), 8729–8743. doi: 10.1021/amt3015399

Luis, A. J. (2000). Atherosclerosis. Nature 407 (6801), 233–241. doi: 10.1038/35025203

Maillard, L., Le Labriolle, A., Brasselet, C., Faivre, B., Durel, N., de Poli, F., et al. (2021). Evaluation of the safety and efficacy of the cobra prf nanoctivated coronary stent in routine, consecutive, prospective, and high-risk patients: the cobra study. Catheter. Cardiovasc. Interv. 98 (1), 45–54. doi: 10.1002/ccd.29065

Marei et al. 10.3389/fphar.2022.8202509

Marei et al. (2022). Advances in endothelial progenitor cells for tissue regeneration. ACS Chem. Biol. 17 (4), e342. doi: 10.1021/acschembio.1c00502

Massia, S. P., and Hubbell, J. A. (1991). Human endothelial cell interactions with surface-coupled adhesion peptides on a nonadhesive glass substrate and two polymeric biomaterials. J. Biomed. Mat. Res. 25 (2), 223–242. doi: 10.1002/jbm.8202509
Statement on nomenclature.

J.M., Khosrtehrani, K., et al. (2017). Endothelial progenitors: A consensus subclassification reveals two distinct cell populations with different identities. BMC Med. Genomics 3, 18. doi:10.1186/s12863-016-0360

Medina, R. J., O’Neill, C. L., Sweeney, M., Gudric-Fuchs, J., Gardiner, T. A., Simpson, D. A., et al. (2010). Molecular analysis of endothelial progenitor cell (EPC) subtypes reveals two distinct cell populations with different identities. BMC Med. Genomics 3, 18. doi:10.1186/s12863-016-0378

Nakazawa, G., Granada, J. F., Alviar, C. L., Teller, A., Kaluza, G. L., Guilmier, M. Y., et al. (2010). Anti-CD34 antibodies immobilized on the surface of siliomus-outgrowth-eliciting cells enhance stem-cell endothelialization. JACC: Cardiovasc. Inter. 3, 1, 18. doi:10.1186/1755-8794-3-18

O’Brien, B., and Carroll, W. (2009). The evolution of cardiovascular stem materials and surfaces in response to clinical drivers: A review. Acta Biomater. 5 (4), 945–958. doi:10.1016/j.actbio.2008.11.012

Ono, T., Asahi, J., Katryk, M. I., and Serruys, P. W. (2005). How to accelerate the endothelialization of stents. Arch. Mal. Coeur Vaiss. 98 (2), 123–126

Otsuka, F., Finn, A. V., Yazdani, S. A., Nakano, M., Kolodgie, F. D., and Virmani, R. (2012). The importance of the endothelium in atherothrombosis and coronary applications. Acta Biomater. 26, 2460–2470. doi:10.1016/j.actbio.2022.08.047

Park, K-S., Kang, S. N., Kim, D. H., Kim, H-B., Im, K. S., Park, W., et al. (2020). Late endothelial progenitor cell-capture stents with CD146 antibody and nanoarchitecture reduce in-stent restenosis and thrombosis. Acta Biomater. 111, 91–101. doi:10.1016/j.actbio.2020.05.011

Pellecchia, F., Passeri, V., Zimarino, M., De Luca, G., De Caterina, R., Mehran, R., et al. (2022). Endothelial progenitor cells in coronary atherosclerosis and percutaneous coronary interventions: A systematic review and meta-analysis. Cardiovasc. Revascularization Med. 42, 94–99. doi:10.1016/j.carrev.2022.02.005

Pellecchia, F., Zimarino, M., De Luca, G., Viceconte, N., Tanzilli, G., and De Caterina, R. (2022). Endothelial progenitor cells in coronary artery disease: from bench to bedside. Stem Cells Transl. Med. 11 (5), 451–460. doi:10.1002/stem.31201

Ross, R. (1993). The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362 (6423), 801–809. doi:10.1038/362801a0

Saito, S., Krucoff, M. W., Nakamura, S., Mehran, R., Maehara, A., Al-Khalidi, H., et al. (2016). Targeting anti-stenosis with RGD- and CXCL1-coated mini stents in mice. PLoS One 11 (5), e0155829. doi:10.1371/journal.pone.0155829

Smeda, D. M., Biché, I., Silvestre, J.-S., Germain, S., Cornet, A., Laurendeau, I., et al. (2008). Bone morphogenetic proteins 2 and 4 are selectively expressed by late outgrowth endothelial progenitor cells and promote neangiogenesis. Arterioscler. Thromb. Vasc. Biol. 28 (12), 2317–2318. doi:10.1161/ATVBAHA.108.1668581

Smith, S.C., Jr., Do, T. J., Jacobs, A. K., Kennedy, J. W., Keserükes, D., Kern, M. J., et al. (2001). ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 pta guidelines)-executive summary: A report of the american college of cardiology/american heart association task force on practice guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the society for cardiac angiography and interventions. Circulation 103 (24), 3019–3041. doi:10.1161/01.HT.103.24.3019

Sousa, J. E., Serruys, P. W., and Costa, M. A. (2003). New frontiers in cardiology: Drug-eluting stents. Part I. Circulation 107 (17), 2274–2279. doi:10.1161/01.CIR.0000069393.41022.90

Spicer, C. D., Pushkow, E. T., and Stevens, M. M. (2018). Achieving controlled biomolecule–biomaterial conjugation. Chem. Rev. 118 (11), 7792–7743. doi:10.1021/acs.chemrev.8b00189

Stassen, O., Muyaert, D. E. P., Bouten, C. V. C., and Hjortnaes, J. (2017). Current challenges in translating tissue-engineered heart valves. Curr. Treat. Options Cardiovasc. Med. 19 (9), 71. doi:10.1007/s11936-017-0566-y

Tian, Y., Seeto, W. J., Plasz-Arias, M. A., Hahn, M. S., and Lipke, E. A. (2022). Endothelial colony forming cell rolling and adhesion supported by peptide-grafted hydrogels. Acta Biomater. 2174, 1–12. doi:10.1016/j.actbio.2019.06.077

Tomasievic, M., Rakovicz, J., Dobric, M., Aleksandrić, S., and Labudovic, M. (2019). Endothelial cell cultures from coronary stent cells - from histology to clinical outcomes. Serum J. Exp. Clin. Res. 0 (0). doi:10.2478/sjrec-2019-0018

Torii, S., Jinouchi, H., Sakamoto, A., Kutyna, M., Cornelissen, A., Kuntz, S. T., et al. (2020). Drug-eluting coronary stent cells: Insights from preclinical and pathology studies. Nat. Rev. Cardiol. 17 (1), 37–51. doi:10.1038/s41569-019-0234-x

Triggle, C. R., Ding, H., Marei, I., Anderson, T. J., and Hollenberg, M. D. (2020). Why the endothelium? The endothelium as a target to reduce diabetes-associated vascular disease. Can. J. Physiol. Pharmacol. 98 (7), 415–430. doi:10.1139/cjpp-2019-0077

Triggle, C. R., Marei, I., Ye, K., Ding, H., Anderson, T. J., and Hollenberg, M. D. (2020). Repurposing metformin for vascular disease. Curr. Med. Chem. 29. doi:10.2174/092986327666620729154615

Van der Heiden, K., Gijsen, F. J., Narracott, A., Hsiao, S., Halliday, L., Gunn, J., et al. (2013). The effects of stenting on shear stress: relevance to endothelial injury and repair. Cardiovasc. Res. 99 (2), 269–275. doi:10.1093/cvr/cct090

Vanhoutte, P. M., and Tang, E. H. (2008). Endothelium-dependent contractions: when do we need to reconsider their identity? Semin. Immunopathol. 30, 586 (22), 2925–2934. doi:10.1111/j.1425-5753.2008.01430.x

Velasco, A. N., Cooper, S. L., and Patterson, C. (2007). Selection and initial characterization of novel peptide ligands that bind specifically to human blood outgrowth endothelial cells. Biotechnol. Bioeng. 98 (1), 306–312. doi:10.1002/bit.21420

Wang, H., Yin, T., Ge, S., Zhang, Q., Dong, Q., Lei, D., et al. (2013). Biofunctionalization of titanium surface with multilayer films modified by heparin-VEGF-boronate complex to improve endothelial cell proliferation and blood compatibility. J. Biomed. Mater. Res. A 101 (2), 413–420. doi:10.1002/jbm.a.34359

Watala, C., Golanski, J., Pluta, J., Boncler, M., Rozalski, M., Luzak, B., et al. (2004). Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb. Res. 113 (2), 101–113. doi:10.1016/j.thromres.2003.12.016
Wawrzyńska, M., Kraskiewicz, H., Paprocka, M., Krawczenko, A., Bielawska-Pohl, A., Bialy, D., et al. (2020). Functionalization with a VEGFR2-binding antibody fragment leads to enhanced endothelialization of a cardiovascular stent in vitro and in vivo. J. Biomed. Mat. Res. B Appl. Biomater. 108 (1), 213–224. doi:10.1002/jbm.b.34380

WHO (2017). Cardiovascular diseases (CVDs) Fact Sheet. Turkey: WHO.

Wiviott, S. D., Braunwald, E., Angiolillo, D. J., Meisel, S., Dalby, A. J., Verheugt, F. W., et al. (2008). Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial Infarction 38. Circulation 118 (16), 1626–1636. doi:10.1161/CIRCULATIONAHA.108.791061

Wu, K. K., and Thiagarajan, P. (1996). Role of endothelium in thrombosis and hemostasis. Annu. Rev. Med. 47 (0066-4219), 315–331. doi:10.1146/annurev.med.47.1.315

Yoder, M. C. (2012). Human endothelial progenitor cells. Cold Spring Harb. Perspect. Med. 2 (7), a006692. doi:10.1101/cshperspect.a006692

Yoder, M. C., Mead, L. E., Prater, D., Krier, T. R., Mroueh, K. N., Li, F., et al. (2007). Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 109 (5), 1801–1809. doi:10.1182/blood-2006-08-043471

Yu, W. P., Ding, J. L., Liu, X. L., Zhu, G. D., Lin, F., Xu, J. J., et al. (2021). Titanium dioxide nanotubes promote M2 polarization by inhibiting macrophage glycolysis and ultimately accelerate endothelialization. Immun. Inflamm. Dis. 9 (3), 746–757. doi:10.1002/iid3.429

Yuan, J., and Xu, G. M. (2018). Early and late stent thrombosis in patients with versus without diabetes mellitus following percutaneous coronary intervention with drug-eluting stents: A systematic review and meta-analysis. Am. J. Cardiovasc. Drugs 18 (6), 483–492. doi:10.1007/s40256-018-0295-y

Zentilin, L., Tafaro, S., Zacchigna, S., Arsic, N., Pattarini, L., Sinigaglia, M., et al. (2006). Bone marrow mononuclear cells are recruited to the sites of VEGF-induced neovascularization but are not incorporated into the newly formed vessels. Blood 107 (9), 3546–3554. doi:10.1182/blood-2005-08-2215

Zhang, H-f., Wang, Y-l., Tan, Y-z., Wang, H-l., Tao, P., and Zhou, P. (2019). Enhancement of cardiac lymphangiogenesis by transplantation of CD34+VEGFR-3+ endothelial progenitor cells and sustained release of VEGF-C. Basic Res. Cardiol. 114 (6), 43. doi:10.1007/s00395-019-0752-z

Zhang, L., Zhu, J., Du, R., Zhu, Z., Zhang, J., Han, W., et al. (2011). Effect of recombinant human SDF-1a on re-endothelialization after sirolimus-eluting stent implantation in rabbit aorta abdominalis. Life Sci. 89 (25 26), 926–930. doi:10.1016/j.lfs.2011.09.020